UCSF Insights
Psychedelics as Breakthrough Therapies
Tuesday, May 23, 2023
5:00 p.m. Pacific time
Recent research at UCSF and other institutions around the world is showing that psychedelic therapies may have transformative effects across the health spectrum, including real potential as treatments for a broad range of mental health conditions such as depression and eating disorders. Join us to hear from our panel of UCSF experts about this emerging field, and bring your questions for the Q&A portion of the event.
More info
More info
Featuring
Person Picture
Joshua Woolley, MD, PhD
Person Title
UCSF Department of Psychiatry and Behavioral Sciences
Dr. Woolley is a physician and neuroscientist who directs UCSF’s Translational Psychedelic Research (TrPR) Program. The program brings together multidisciplinary scientists and care providers to learn how psychedelic compounds affect the brain and other organ systems. Currently, the TrPR Program conducts mechanistic clinical trials examining psychedelic therapy for depression, bipolar disorder, Parkinson’s disease, and chronic pain.
Person Picture
Ellen Bradley, MD
Person Title
UCSF Department of Psychiatry and Behavioral Sciences
Dr. Bradley is associate director of the TrPR Program as well as lead psychiatrist for the San Francisco Veteran’s Affairs Parkinson’s Disease Research, Education, and Clinical Center (PADRECC). Her work focuses on developing novel treatments for illnesses that span the psychiatry-neurology divide, including neurodegenerative and chronic pain disorders.
Person Picture
Marissa Raymond-Flesch, MD, MPH
Person Title
UCSF Division of Adolescent and Young Adult Medicine and Philip R. Lee Institute for Health Policy Studies
Dr. Raymond-Flesch practices adolescent medicine with patients 12-26 years old, including treatment of depression, anxiety, and eating disorders. Her current research focuses on the effectiveness of psilocybin-assisted psychotherapy for the treatment of young adults with refractory anorexia nervosa, which typically begins in adolescence and is among the most deadly of all mental illnesses, with a 6%-10% fatality rate.
Person Picture
Robin Carhart-Harris, PhD
Person Title
Ralph Metzner Distinguished Professor
UCSF Department of Neurology and Department of Psychiatry and Behavioral Sciences
Dr. Carhart-Harris, a renowned leader in neuroscience research, focuses on advancing the science of psychedelic compounds, a class of psychoactive substances that change users’ perceptions, moods, and cognitive processes. He has designed human brain-imaging studies involving psilocybin – the compound found in psychedelic mushrooms – LSD, MDMA (ecstasy/molly), and DMT, as well as clinical trials of psilocybin for depression and other mental illnesses.
